Clinical Trials Browser

inavolisib × 90 days × Clear all

NCT07287150 2026-06-04

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06790693 2026-06-03

INAVO123

Phase 3 Recruiting

Breast Neoplasms

NCT04449874 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07618390 2026-06-01

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05894239 2026-05-29

INAVO122

Phase 3 Recruiting

Breast Neoplasms

NCT06496568 2026-05-27

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Phase 1 Active not recruiting

PIK3CA-Mutated Cancers

NCT04929223 2026-05-26

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07347600 2026-05-18

reaINAVO

Breast Neoplasms

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05862285 2026-05-12

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07368998 2026-05-11

optINAVO

Phase 2 Recruiting

Breast Neoplasms

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT05646862 2026-05-06

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT07543250 2026-04-21

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Not yet recruiting

Breast Neoplasms

NCT07522697 2026-04-13

MITO END-4

Phase 2 Not yet recruiting

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms